T. Rowe Price Associates
LCTX icon

T. Rowe Price Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

T. Rowe Price Associates’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Buy
+151,233
New +$209K ﹤0.01% 3009
2025
Q2 		– Sell
-72,398
Closed -$33K – 3105
2025
Q1 		$33K Sell
72,398
-35,806
-33% -$21K ﹤0.01% 2974
2024
Q4 		$55K Hold
108,204
– – ﹤0.01% 2928
2024
Q3 		$98K Sell
108,204
-57,190
-35% -$53K ﹤0.01% 2824
2024
Q2 		$164K Buy
165,394
+4,080
+3% +$4.51K ﹤0.01% 2638
2024
Q1 		$239K Buy
161,314
+70,418
+77% +$79.8K ﹤0.01% 2537
2023
Q4 		$100K Buy
90,896
+5,560
+7% +$6.09K ﹤0.01% 2717
2023
Q3 		$101K Hold
85,336
– – ﹤0.01% 2669
2023
Q2 		$121K Sell
85,336
-3,764
-4% -$5.2K ﹤0.01% 2661
2023
Q1 		$134K Hold
89,100
– – ﹤0.01% 2625
2022
Q4 		$104K Hold
89,100
– – ﹤0.01% 2712
2022
Q3 		$101K Buy
89,100
+16,700
+23% +$24.5K ﹤0.01% 2723
2022
Q2 		$114K Buy
72,400
+11,309
+19% +$14.9K ﹤0.01% 2731
2022
Q1 		$94K Buy
61,091
+2,700
+5% +$4.19K ﹤0.01% 2857
2021
Q4 		$143K Sell
58,391
-57,300
-50% -$134K ﹤0.01% 2819
2021
Q3 		$292K Buy
115,691
+61,960
+115% +$159K ﹤0.01% 2589
2021
Q2 		$153K Buy
53,731
+9,931
+23% +$25.7K ﹤0.01% 2780
2021
Q1 		$103K Buy
+43,800
New +$105K ﹤0.01% 2778

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

T. Rowe Price Associates's LCTX Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 151,233 shares worth $199K. The stake represents ﹤0.01% of the portfolio and ranks #3009 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in LCTX as recently as Q1 2025.

T. Rowe Price Associates first reported a position in LCTX in Q1 2021 and has held it in 18 quarters since. The position peaked at $292K in Q3 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • T. Rowe Price Associates held 151,233 shares of Lineage Cell Therapeutics worth $199K as of Q2 2026.
  • Lineage Cell Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3009 holding.
  • T. Rowe Price Associates first reported a position in Lineage Cell Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • T. Rowe Price Associates's Lineage Cell Therapeutics position peaked at $292K in Q3 2021.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.